OncoMatch/Clinical Trials/NCT05239546
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
Is NCT05239546 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Dostarlimab for colon cancer.
Treatment: Dostarlimab — This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR deficient mismatch repair (dMMR) by IHC
Biopsy proven dMMR (by IHC)
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational therapy
Received investigational therapy less than or equal to 3 months, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.
Cannot have received: major surgery
Major surgery less than or equal to 3 weeks prior to initiating protocol therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/µL; Platelets ≥ 100,000/µL; Hemoglobin ≥ 9 g/dL
Kidney function
Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance 60mL/min using Cockcroft-Gault equation
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 2.0 in patients with known Gilberts syndrome) OR direct bilirubin ≤ 1 x ULN; AST and ALT ≤ 3.0 x ULN
Absolute neutrophil count ≥ 1,500/µL; Platelets ≥ 100,000/µL; Hemoglobin ≥ 9 g/dL; Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance 60mL/min; Total bilirubin ≤ 1.5 x ULN (≤ 2.0 in patients with known Gilberts syndrome) OR direct bilirubin ≤ 1 x ULN; AST and ALT ≤ 3.0 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Iowa Hospitals & Clinics · Iowa City, Iowa
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify